WADA makes deal with Pfizer to help combat doping

Pfizer will review substances under development to see if they share similarities with PEDs

Multi-national pharmaceutical corporation Pfizer signed a deal with the World Anti-Doping Agency (WADA) on Wednesday, to help identify substances that could pose a high risk of potentially being used as a performance enhancing drug (PED) by athletes.

The agreement will see Pfizer review substances under development to see how they work in the human body and if they share similarities to any drugs previously used as PEDs.

Thank you for reading 20 articles this month* Join now for unlimited access

Enjoy your first month for just £1 / $1 / €1

*Read 5 free articles per month without a subscription

Join now for unlimited access

Try first month for just £1 / $1 / €1

Richard Windsor

Follow on Twitter: @richwindy

Richard is digital editor of Cycling Weekly. Joining the team in 2013, Richard became editor of the website in 2014 and coordinates site content and strategy, leading the news team in coverage of the world's biggest races and working with the tech editor to deliver comprehensive buying guides, reviews, and the latest product news.

An occasional racer, Richard spends most of his time preparing for long-distance touring rides these days, or getting out to the Surrey Hills on the weekend on his Specialized Tarmac SL6 (with an obligatory pub stop of course).